Interview: Pressures On US Generics Industry Go Beyond Current Price Squeeze
Generics firms in the US must fight back against brand industry attempts to thwart competition as well as regulatory obstacles looming on the horizon, while continuing to grapple with ongoing price erosion, says AAM president and CEO Chip Davis.
You may also be interested in...
Beximco has struck a deal worth nearly $50m to acquire a majority stake in Sanofi Bangladesh, allowing the firm to expand in its domestic market.
After almost a year as CEO of Centrient, Rex Clements reflects on the company’s experiences operating amid a pandemic that has underlined the importance of a diversified supply chain, while also highlighting the firm’s sustainable manufacturing initiatives and calling for non-price criteria to be taken into account by procurement processes, in an exclusive interview with Generics Bulletin.
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.